Sanofi’s new atopic dermatitis launch Dupixent has hit a roadblock with the influential cost-effectiveness gatekeepers in England. The National Institute for Health and Care Excellence rejected the blockbuster hopeful, despite finding that it’s an innovative drug for patients who have a strong need for new treatments.
The obstacle? It’s likely price, if NICE history holds. The agency found that Dupixent is a “step change” in managing the disease, Sanofi said Tuesday, but couldn’t sign off on its use because of cost-effectiveness concerns. The guidance isn’t final, and the process now goes to a consultation period until April 24.